The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG

Abstract

The objective of the study: to assess the effect of current chemotherapy on QT interval length in tuberculosis patients suffering from multiple/extensive drug resistance (M/XDR). Subjects and methods. 87 patients (new cases and relapses) with destructive pulmonary MDR/XDR tuberculosis were followed up. Results. During anti-tuberculosis therapy with regime V, the prolongation of QTc interval in the range of 450-500 ms was observed in 27.6% of MDR/XDR tuberculosis patients, which was most often recorded at the end of the 12th week of chemotherapy. The prolongation of QTc interval was reversible (in the majority of patients, QTc returned to its original values), it was not accompanied by clinical manifestations and ECG signs of ventricular arrhythmias, and did not require additional therapeutic measures (not in a single case). MDR/XDR tuberculosis patients receiving treatment with bedaquiline and fluoroquinolones need regular ECG examination to monitor changes in the QTc interval prolongation.

Keywords

• удлинение интервала отс
• химиотерапия туберкулеза
• туберкулез с млу/шлу возбудителя
• бедаквилин